NCT00813956 2016-03-17A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast CancerSanofiPhase 2 Completed80 enrolled
NCT01045304 2014-01-14Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast CancerSanofiPhase 2 Completed163 enrolled
NCT00540358 2012-12-28A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast CancerSanofiPhase 2 Completed123 enrolled